Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes

Urology

Volumn 82, Issue 2, 2013, Pages 321-326

  Kaplan, Alan L ^a   Hu, Jim C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANDROGEN THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; COMORBIDITY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SENESCENCE; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; AGED; ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROPENSITY SCORE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SEER PROGRAM; TESTOSTERONE; UNITED STATES; WATCHFUL WAITING;

EID: 84880923151     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.03.049     Document Type: Article

References (30)

1. P.N. Surampudi, C. Wang, and R. Swerdloff Hypogonadism in the aging male diagnosis, potentials benefits, and risks of testosterone replacement therapy Int J Endocrinol 2012 2012 625434
2. S.M. Harman, E.J. Metter, and J.D. Tobin Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging J Clin Endocrinol Metab 86 2001 724 731
3. F.C. Wu, A. Tajar, and J.M. Beynon Identification of late-onset hypogonadism in middle-aged and elderly men N Engl J Med 363 2010 123 135
4. A. Tajar, I.T. Huhtaniemi, and T.W. O'Neill Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study J Clin Endocrinol Metab 97 2012 1508 1516
5. A. Morgentaler Testosterone and prostate cancer: what are the risks for middle-aged men? Urol Clin N Am 38 2011 119 124
6. C. Wang, G. Cunningham, and A. Dobs Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone density in hypogonadal men J Clin Endocrinol Metab 89 2004 2085 2098
7. A. Morgentaler Testosterone and prostate cancer: an historical perspective on a modern myth Eur Urol 50 2006 935 938
8. C. Huggins, and C.V. Hodges Studies on prostate cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic cercinoma of the prostate Cancer Res 1 1941 293 297
9. J.E. Fowler, and W.F. Whitmore Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone J Urol 126 1981 372 375
10. O.M. Calof, A.B. Singh, and M.L. Lee Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials J Gerontol A Biol Sci Med Sci 60 2005 1451
11. M.R., Feneley, and M. Carruthers Is testosterone treatment good for the prostate? Study of safety during long-term treatment J Sex Med 9 2012 2138 2149
12. A.L. Potosky, G.F. Riley, and J.D. Lubitz Potential for cancer related health services research using a linked Medicare-tumor registry database Med Care 31 1993 732 748
13. C. Zippin, D. Lum, and B.F. Hankey Completeness of hospital cancer case reporting from the SEER program of the National Cancer Institute Cancer 76 1995 2343 2350
14. C.N. Klabunde, A.L. Potosky, and J.M. Legler Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258 1267
15. J.C. Hu, S.B. Williams, and A.J. O'Malley Androgren-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism Eur Urol 61 2012 1119 1128
16. P.R. Rosenbaum, and D.B. Rubin Reducing bias in observational studies using subclassifications on the propensity score J Am Stat Assoc 79 1984 516 524
17. D.B. Rubin Estimating causal effects from large data sets using propensity scores Ann Intern Med 127 1997 757 763
18. S.A. Kaplan, A.G. Meehan, and A. Shah The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 176 2006 1524 1527
19. A.M. Traish, F. Saad, and A. Guay The dark side of testosterone deficiency II: type 2 diabetes and insulin resistance J Androl 30 2009 23 32
20. A.M. Traish, F. Saad, and R.J. Feeley The dark side of testosterone deficiency III: cardiovascular disease J Androl 30 2009 477 494
21. A. Kaltenboeck, S. Foster, and J. Ivanova The direct and indirect costs among U.S. privately insured employees with hypogonadism J Sex Med 9 2012 2438 2447
22. R. Haring, S.E. Baumeister, and H. Völzke Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men Int J Androl 33 2010 800 809
23. M. Khera, R.K. Bhattacharya, and G. Blick The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS) Aging Male 15 2012 14 21
24. M. Khera, R.K. Bhattacharya, and G. Blick Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the US (TRiUS) J Sex Med 8 2011 3204 3213
25. A.B. Araujo, A.B. O'Donnell, and D.J. Brambilla Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study J Clin Endocrinol Metab 89 2004 5920 5926
26. L.J. Gooren, and H.M. Behre Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010 Aging Male 15 2012 22 27
27. E.L. Rhoden, and A. Morgentaler Risks of testosterone replacement therapy and recommendations for monitoring N Engl J Med 350 2004 482 492
28. R. Shabsigh, E.D. Crawford, and A. Nehra Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Int J Impot Res 21 2009 9 23
29. K. Lin, J.M. Croswell, and H. Koenig Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force Report No.: 12-05160-EF-1 2011 Agency for Healthcare Research and Quality (US) Rockville (MD)
30. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328